Advertisement

Intestinal lipase inhibitors

  • John P. H. Wilding
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Given that malabsorptive surgery is such an effective treatment for obesity, it is perhaps not surprising that attempts have been made to use drugs that inhibit the absorption of macronutrients to treat obesity. Acarbose, an inhibitor of carbohydrate absorption has been shown to have modest efficacy in the treatment of diabetes, but does not cause weight loss. Dietary fat is the most energy dense macronutrient, and blockade of absorption of fat is therefore a logical target for an anti-obesity drug. Orlistat, an inhibitor of pancreatic and intestinal lipases, was originally developed as a possible treatment for dyslipidaemia, but the focus switched to obesity once its ability to promote a negative energy balance was recognised.

Keywords

Pancreatic Lipase Lipase Inhibitor Orlistat Group Intestinal Lipase Pancreatic Cholesterol Esterase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weibel EK, Hadvary P, Hochuli E (1987) Lipstatin, an inhbitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot 40: 1081–1085PubMedGoogle Scholar
  2. 2.
    Hochuli E, Kupfer E, Maurer R (1987) Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxitricini. II Chemistry and Structure elucidation. J Antibiot 40: 1086–1091PubMedGoogle Scholar
  3. 3.
    Hadvary P, Sidler W, Meister W, Vetter W, Wolfer H (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active-site serine of pancreatic lipase. J Biol Chem 266: 2021–2027PubMedGoogle Scholar
  4. 4.
    Borgstrom B (1988) Mode of action of tetrahydrolipstatin: A derivative of the naturally occurring lipase inhibitor lipstatin. Biochem Biophys Acta 962: 308–316PubMedGoogle Scholar
  5. 5.
    Guerciolini R (1997) Mode of action of orlistat. Int J Obesity 21: S12–S23Google Scholar
  6. 6.
    Zhi JG, Melia AT, Funk C, VigerChougnet A, Hopfgartner G, Lausecker B, Wang K, Fulton JS, Gabriel L, Mulligan TE (1996) Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 36: 1006–1011PubMedCrossRefGoogle Scholar
  7. 7.
    Zhi JG, Melia AT, Eggers H, Joly R, Patel IH (1995) Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy-human volunteers. J Clin Pharmacol 35: 1103–1108PubMedGoogle Scholar
  8. 8.
    Orlistat Product Monograph 1 (1998) F-Hoffmann-La Roche Ltd.Google Scholar
  9. 9.
    Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH (1994) Retrospective population-based analysis of the dose-response (Fecal fat excretion) Relationship of orlistat in normal and obese volunteers. Clin Pharmacol Therapeutics 56: 82–85CrossRefGoogle Scholar
  10. 10.
    Melia AT, KossTwardy SG, Zhi JG (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36: 647–653PubMedGoogle Scholar
  11. 11.
    Zhi JG, Melia AT, Koss Twardy SG, Arora S, Patel IH (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 36: 152–159PubMedGoogle Scholar
  12. 12.
    Drent ML, Larsson I, Williamolsson T, Quaade F, Czubayko F, Vonbergmann K, Strobel W, Sjostrom L, vanderVeen EA (1995) Orlistat (Ro-18-0647), A lipase inhibitor, in the treatment of human obesity — a multiple-dose study. Int J Obesity 19: 221–226Google Scholar
  13. 13.
    Bennett PK, Li YT, Edom R, Henion J (1997) Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18–0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry. J Mass Spectrometry 32: 739–749CrossRefGoogle Scholar
  14. 14.
    Weber C, Tam YK, SchmidtkeSchrezenmeier G, Jonkmann JHG, vanBrummelen P (1996) Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 51: 87–90PubMedCrossRefGoogle Scholar
  15. 15.
    Melia AT, Mulligan TE, Zhi JG (1996) The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 36: 654–658PubMedGoogle Scholar
  16. 16.
    Melia AT, Zhi JG, KossTwardy SG, Min BH, Smith BL, Freundlich NL, Arora S, Passe SM (1995) The influence of reduced dietary-fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy-volunteers. J Clin Pharmacol 35: 840–843PubMedGoogle Scholar
  17. 17.
    Zhi J, Melia AT, KossTwardy SG, Min B, Guerciolini R, Freundlich NL, Milla G, Patel IH (1995) The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthyvolunteers. J Clin Pharmacol 35: 521–525PubMedGoogle Scholar
  18. 18.
    Hartmann D, Guzelban C, Zuiderwijk PBM, Odink J (1996) Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 50: 421–424PubMedCrossRefGoogle Scholar
  19. 19.
    Melia AT, Zhi J, Zelasko R, Hartmann D, Guzelhan C, Guerciolini R, Odink J (1998) The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 54: 773–777PubMedCrossRefGoogle Scholar
  20. 20.
    Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167–172PubMedCrossRefGoogle Scholar
  21. 21.
    Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat — A randomized controlled trial. JAMA 281: 235–242PubMedCrossRefGoogle Scholar
  22. 22.
    Davidson M (1997) A 2 year, US, randomized, controlled study of orlistat, a gastrointestinal lipase inhibitor, for obesity treatment. JAMA 96: 4119Google Scholar
  23. 23.
    Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K (1996) A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 4(3): 263–270PubMedGoogle Scholar
  24. 24.
    James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356(9248): 2119–2125PubMedCrossRefGoogle Scholar
  25. 25.
    Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Eng J Med 353(20): 2121–2134PubMedCrossRefGoogle Scholar
  26. 26.
    Elfhag K, Finer N, Rossner S (2007) Who will lose weight on orlistat and sibutramine? Psychological correlates of success. Diabetes Obes Metab 26 (ePub ahead of print)Google Scholar
  27. 27.
    Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, Teramo K, Yki-Jarvinen H (2004) Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutrition 79(1): 22–30Google Scholar
  28. 28.
    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J et al. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes — A 1-year randomized double-blind study. Diabetes Care 21: 1288–1294PubMedCrossRefGoogle Scholar
  29. 29.
    Broom I, Wilding J, Stott P, Myers N (2002) Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Practice 56(7): 494–499Google Scholar
  30. 30.
    Lindgarde F (2000) The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Internal Med 248(3): 245–254CrossRefGoogle Scholar
  31. 31.
    Sharma AM, Golay A (2001) Effect of weight management with orlistat on blood pressure in obese patients with hypertension. Obesity Res 9: 189SGoogle Scholar
  32. 32.
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 27(1): 155–161PubMedCrossRefGoogle Scholar
  33. 33.
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J (2005) Effect of orlistat on weight and body composition in obese adolescents — A randomized controlled trial. JAMA 293(23): 2873–2883PubMedCrossRefGoogle Scholar
  34. 34.
    Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P (2007) Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obesity 31(3): 494–499CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • John P. H. Wilding
    • 1
  1. 1.Diabetes and Endocrinology Clinical Research Group, Clinical Sciences CentreUniversity Hospital AintreeLiverpoolUK

Personalised recommendations